X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
71
PharmaCompass offers a list of Topiramate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Topiramate manufacturer or Topiramate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Topiramate manufacturer or Topiramate supplier.
PharmaCompass also assists you with knowing the Topiramate API Price utilized in the formulation of products. Topiramate API Price is not always fixed or binding as the Topiramate Price is obtained through a variety of data sources. The Topiramate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A MolPort-001-615-062 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of MolPort-001-615-062, including repackagers and relabelers. The FDA regulates MolPort-001-615-062 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. MolPort-001-615-062 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of MolPort-001-615-062 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A MolPort-001-615-062 supplier is an individual or a company that provides MolPort-001-615-062 active pharmaceutical ingredient (API) or MolPort-001-615-062 finished formulations upon request. The MolPort-001-615-062 suppliers may include MolPort-001-615-062 API manufacturers, exporters, distributors and traders.
click here to find a list of MolPort-001-615-062 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A MolPort-001-615-062 DMF (Drug Master File) is a document detailing the whole manufacturing process of MolPort-001-615-062 active pharmaceutical ingredient (API) in detail. Different forms of MolPort-001-615-062 DMFs exist exist since differing nations have different regulations, such as MolPort-001-615-062 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A MolPort-001-615-062 DMF submitted to regulatory agencies in the US is known as a USDMF. MolPort-001-615-062 USDMF includes data on MolPort-001-615-062's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The MolPort-001-615-062 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of MolPort-001-615-062 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The MolPort-001-615-062 Drug Master File in Japan (MolPort-001-615-062 JDMF) empowers MolPort-001-615-062 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the MolPort-001-615-062 JDMF during the approval evaluation for pharmaceutical products. At the time of MolPort-001-615-062 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of MolPort-001-615-062 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a MolPort-001-615-062 Drug Master File in Korea (MolPort-001-615-062 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of MolPort-001-615-062. The MFDS reviews the MolPort-001-615-062 KDMF as part of the drug registration process and uses the information provided in the MolPort-001-615-062 KDMF to evaluate the safety and efficacy of the drug.
After submitting a MolPort-001-615-062 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their MolPort-001-615-062 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of MolPort-001-615-062 suppliers with KDMF on PharmaCompass.
A MolPort-001-615-062 CEP of the European Pharmacopoeia monograph is often referred to as a MolPort-001-615-062 Certificate of Suitability (COS). The purpose of a MolPort-001-615-062 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of MolPort-001-615-062 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of MolPort-001-615-062 to their clients by showing that a MolPort-001-615-062 CEP has been issued for it. The manufacturer submits a MolPort-001-615-062 CEP (COS) as part of the market authorization procedure, and it takes on the role of a MolPort-001-615-062 CEP holder for the record. Additionally, the data presented in the MolPort-001-615-062 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the MolPort-001-615-062 DMF.
A MolPort-001-615-062 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. MolPort-001-615-062 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of MolPort-001-615-062 suppliers with CEP (COS) on PharmaCompass.
A MolPort-001-615-062 written confirmation (MolPort-001-615-062 WC) is an official document issued by a regulatory agency to a MolPort-001-615-062 manufacturer, verifying that the manufacturing facility of a MolPort-001-615-062 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting MolPort-001-615-062 APIs or MolPort-001-615-062 finished pharmaceutical products to another nation, regulatory agencies frequently require a MolPort-001-615-062 WC (written confirmation) as part of the regulatory process.
click here to find a list of MolPort-001-615-062 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing MolPort-001-615-062 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for MolPort-001-615-062 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture MolPort-001-615-062 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain MolPort-001-615-062 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a MolPort-001-615-062 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of MolPort-001-615-062 suppliers with NDC on PharmaCompass.
MolPort-001-615-062 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of MolPort-001-615-062 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right MolPort-001-615-062 GMP manufacturer or MolPort-001-615-062 GMP API supplier for your needs.
A MolPort-001-615-062 CoA (Certificate of Analysis) is a formal document that attests to MolPort-001-615-062's compliance with MolPort-001-615-062 specifications and serves as a tool for batch-level quality control.
MolPort-001-615-062 CoA mostly includes findings from lab analyses of a specific batch. For each MolPort-001-615-062 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
MolPort-001-615-062 may be tested according to a variety of international standards, such as European Pharmacopoeia (MolPort-001-615-062 EP), MolPort-001-615-062 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (MolPort-001-615-062 USP).
Market Place
